Emerging drugs for the treatment of Clostridium difficile.

Emerging drugs for the treatment of Clostridium difficile.
Expert Opin Emerg Drugs. 2019 Mar 06;:
Authors: Cammarota G, Gallo A, Ianiro G, Montalto M
Abstract
Introduction Clostridium difficile, or Clostridioides difficile, (C difficile) infection represents the most common cause of healthcare-associated infection. Over the last decades, the incidence and severity of C difficile infection is rapidly increasing, with a significant impact on morbidity and mortality, and burden on health care system. Orally administered vancomycin and fidaxomicin are the therapeutic options of choice for initial C difficile infection and fecal microbiota transplant for the recurrence infection. Furthermore, in recent years several new antibiotics with narrow-spectrum activity and low intestinal resorption have been developed, including surotomycin, cadazolid, and ridinilazol, and novel toxoid vaccines are expected to be efficacious in the prevention of C difficile infection. Areas covered Literature review was performed to select publications about current guidelines and phase II/III trials on emerging drugs. These include novel antibiotics, monoclonal antibodies, vaccines, and fecal microbiota transplantation. Expert opinion We have today a wide spectrum of promising therapeutic possibilities against infection. Pivotal future clinical trials may be crucial in developing effective strategies to optimize outcomes, mainly in high-risk population.
...

Source: Expert Opinion on Emerging Drugs - March 8, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research